{"id":469430,"date":"2021-04-01T06:58:16","date_gmt":"2021-04-01T10:58:16","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=469430"},"modified":"2021-04-01T06:58:16","modified_gmt":"2021-04-01T10:58:16","slug":"eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\/","title":{"rendered":"EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WALTHAM, Mass., April  01, 2021  (GLOBE NEWSWIRE) &#8212; EyeGate Pharmaceuticals, Inc.\u00a0(NASDAQ: EYEG), (\u201cEyeGate\u201d or the \u201cCompany\u201d), a clinical-stage company developing products for treating inflammatory and immune diseases, today announced that it has appointed Kenneth Gayron and Aron Shapiro to the Company\u2019s Board of Directors, effective immediately. Thomas Hancock, Morton Goldberg, M.D., and Bernard Malfroy-Camine, Ph.D., have stepped down from the board, which is now composed of seven members. Both Mr. Gayron and Mr. Shapiro bring a unique perspective, deep expertise and valuable insight to the Company.<\/p>\n<p>\u201cWe are very pleased to welcome these esteemed leaders to our board as we navigate our path forward, advance our robust clinical pipeline that encompasses a broad range of therapeutic areas and build on our success to date,\u201d said Franz Obermayr, Ph.D., Acting Chief Executive Officer of EyeGate. \u201cMr. Gayron has a strong track record for enhancing operational capabilities to drive growth and Mr. Shapiro\u2019s extensive clinical-regulatory strategy and business development experience will be invaluable assets for EyeGate\u2019s leadership team. They are both tremendous additions to our board, and we look forward to working with them as we continue to translate organizational vision to operational excellence.\u201d<\/p>\n<p>Kenneth Gayron has been appointed to EyeGate\u2019s Board of Directors as Chair of the Audit Committee. In addition to his position on EyeGate\u2019s board, he also currently serves as Chief Financial Officer &amp; Executive Vice President at Avid Technology. At Avid he has been responsible for driving strategic growth initiatives, capital allocation and repositioning the Company with the investment community. Prior to joining Avid, Mr. Gayron served as Chief Financial Officer and interim Chief Executive Officer for Numerex, where he played a significant role in the company\u2019s acquisition by Sierra Wireless and was Chief Financial Officer for Osmotica Pharmaceutical Inc. Prior to his career in senior finance management, Mr. Gayron worked in investment banking with UBS Investment Bank and CIBC World Markets. Mr. Gayron earned his MBA from Cornell University and his B.S. in finance from Boston College.<\/p>\n<p>Aron Shapiro is currently Senior Vice President and Partner in the Asset Development &amp; Partnering group at Ora, Inc. He is responsible for Ora\u2019s strategic partnering activities where he evaluates and performs diligence on new investment opportunities. Prior to moving to the Asset Development &amp; Partnering group, Mr. Shapiro was responsible for establishing and leading clinical regulatory strategy and clinical operations across a number of anterior and posterior segment indications for Ora\u2019s service business in ophthalmology and was responsible for Ora\u2019s business development and international growth strategy. Mr. Shapiro earned his B.S. in biological chemistry from Bates College.<\/p>\n<p>\n        <strong>About EyeGate<\/strong><br \/>\n        <br \/>EyeGate is a clinical-stage pharmaceutical company developing and commercializing products for treating inflammatory and immune diseases. PP-001, EyeGate\u2019s lead clinical-stage drug product, is a next-generation, non-steroidal, immuno-modulatory and small-molecule inhibitor of Dihydroorotate Dehydrogenase (\u201cDHODH\u201d) with best-in-class picomolar potency and a validated immune modulating mechanism designed to overcome the off-target side effects and safety issues associated with DHODH inhibitors. PP-001 is being developed in multiple formulations for various indications, including ophthalmic, intravenous, and oral formulations. In addition, EyeGate is developing Ocular Bandage Gel (\u201cOBG\u201d), a modified form of the natural polymer hyaluronic acid, designed to protect the ocular surface to permit re-epithelialization of the cornea and improve ocular surface integrity. OBG has unique properties that help hydrate and protect the ocular surface. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EZp2DoLlxQWtpSj_Oqf-hWdNEsfA-VTVIRsnPTXdhqeVMOT1Oe8QBQo6Qngnb_3zXw9VZzTK8qzbvtxsiyCh0j7KIcJ0PlJNe1fkn3P4eoU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.EyeGatePharma.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>Some of the statements in this press release are \u201cforward-looking\u201d and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These \u201cforward-looking\u201d statements include statements relating to, among other things, the commercialization efforts and other regulatory or marketing approval efforts pertaining to EyeGate\u2019s products, including EyeGate\u2019s PP-001 and OBG products, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, certain risk factors described under the heading \u201cRisk Factors\u201d contained in EyeGate\u2019s Annual Report on Form 10-K filed with the SEC on\u00a0March 25, 2021 or described in EyeGate\u2019s other public filings. EyeGate\u2019s results may also be affected by factors of which EyeGate is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. EyeGate expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.<\/p>\n<p>\n        <strong>Contact<\/strong><br \/>\n        <br \/>Corey Davis, Ph.D.<br \/>LifeSci Advisors<br \/>(212) 915-2577<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=O5QVea1Ci3j2H6aCSlL36d6MF0mcrC8Kj6ORk80A4C8mCVU0bUf3neI0G8T_TbHN5mHfAK94b6z0fvaLdGUs8ACs_Zf_9hoeIlCZKXTnWTqWEjT0DxolRbcOFXDxTrCr\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">cdavis@lifesciadvisors.com<\/a><\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTk4NiM0MTAxNzAwIzUwMDA3NjU2MQ==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/1e8db867-92c2-4e49-a26c-15ed8c1ce3c1\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WALTHAM, Mass., April 01, 2021 (GLOBE NEWSWIRE) &#8212; EyeGate Pharmaceuticals, Inc.\u00a0(NASDAQ: EYEG), (\u201cEyeGate\u201d or the \u201cCompany\u201d), a clinical-stage company developing products for treating inflammatory and immune diseases, today announced that it has appointed Kenneth Gayron and Aron Shapiro to the Company\u2019s Board of Directors, effective immediately. Thomas Hancock, Morton Goldberg, M.D., and Bernard Malfroy-Camine, Ph.D., have stepped down from the board, which is now composed of seven members. Both Mr. Gayron and Mr. Shapiro bring a unique perspective, deep expertise and valuable insight to the Company. \u201cWe are very pleased to welcome these esteemed leaders to our board as we navigate our path forward, advance our robust clinical pipeline that encompasses a broad range of therapeutic areas and build on &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-469430","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., April 01, 2021 (GLOBE NEWSWIRE) &#8212; EyeGate Pharmaceuticals, Inc.\u00a0(NASDAQ: EYEG), (\u201cEyeGate\u201d or the \u201cCompany\u201d), a clinical-stage company developing products for treating inflammatory and immune diseases, today announced that it has appointed Kenneth Gayron and Aron Shapiro to the Company\u2019s Board of Directors, effective immediately. Thomas Hancock, Morton Goldberg, M.D., and Bernard Malfroy-Camine, Ph.D., have stepped down from the board, which is now composed of seven members. Both Mr. Gayron and Mr. Shapiro bring a unique perspective, deep expertise and valuable insight to the Company. \u201cWe are very pleased to welcome these esteemed leaders to our board as we navigate our path forward, advance our robust clinical pipeline that encompasses a broad range of therapeutic areas and build on &hellip; Continue reading &quot;EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-01T10:58:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTk4NiM0MTAxNzAwIzUwMDA3NjU2MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors\",\"datePublished\":\"2021-04-01T10:58:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\\\/\"},\"wordCount\":819,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTk4NiM0MTAxNzAwIzUwMDA3NjU2MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\\\/\",\"name\":\"EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTk4NiM0MTAxNzAwIzUwMDA3NjU2MQ==\",\"datePublished\":\"2021-04-01T10:58:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTk4NiM0MTAxNzAwIzUwMDA3NjU2MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTk4NiM0MTAxNzAwIzUwMDA3NjU2MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors - Market Newsdesk","og_description":"WALTHAM, Mass., April 01, 2021 (GLOBE NEWSWIRE) &#8212; EyeGate Pharmaceuticals, Inc.\u00a0(NASDAQ: EYEG), (\u201cEyeGate\u201d or the \u201cCompany\u201d), a clinical-stage company developing products for treating inflammatory and immune diseases, today announced that it has appointed Kenneth Gayron and Aron Shapiro to the Company\u2019s Board of Directors, effective immediately. Thomas Hancock, Morton Goldberg, M.D., and Bernard Malfroy-Camine, Ph.D., have stepped down from the board, which is now composed of seven members. Both Mr. Gayron and Mr. Shapiro bring a unique perspective, deep expertise and valuable insight to the Company. \u201cWe are very pleased to welcome these esteemed leaders to our board as we navigate our path forward, advance our robust clinical pipeline that encompasses a broad range of therapeutic areas and build on &hellip; Continue reading \"EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-01T10:58:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTk4NiM0MTAxNzAwIzUwMDA3NjU2MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors","datePublished":"2021-04-01T10:58:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\/"},"wordCount":819,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTk4NiM0MTAxNzAwIzUwMDA3NjU2MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\/","name":"EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTk4NiM0MTAxNzAwIzUwMDA3NjU2MQ==","datePublished":"2021-04-01T10:58:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTk4NiM0MTAxNzAwIzUwMDA3NjU2MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTk4NiM0MTAxNzAwIzUwMDA3NjU2MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/469430","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=469430"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/469430\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=469430"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=469430"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=469430"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}